08.01.2019 • NewsDede WillamsFTCIndorama Ventures

FTC Clears Purchase of M&G’s Texas PET Plant

FTC Clears Purchase of M&G’s Texas PET Plant (c) Picsfive/Shutterstock
FTC Clears Purchase of M&G’s Texas PET Plant (c) Picsfive/Shutterstock

Thai polyester giant Indorama Ventures (IVL) and its two partners in the joint acquisition vehicle CC Polymers have received all regulatory clearance from the US Federal Trade Commission (FTC) for their proposed joint asset purchase of insolvent PET producer M&G USA and its affiliated debtors.

The consortium founded in March 2018, which also includes Taiwan’s Far Eastern New Century (FENC) and Mexico’s Alpek, offered a binding bid of $1.125 billion in cash and other capital contributions for the Italian company’s unfinished production complex at Corpus Christi Texas, USA. The facilities have nameplate capacity to produce 1.3 million t/y of PTA and 1.1 million t/y of PET.

Certain intellectual property and a desalination/boiler plant designed to supply energy and water to what will be the world’s largest single-line vertically integrated PTA-PET production line and the largest PTA plant in the Americas are also part of the deal.

Under the terms of the joint venture agreement, each of the three partners – who are believed to be M&G’s biggest creditors – will receive a third of the PTA and PET produced, with each securing its own raw materials separately  Each of the companies will also independently sell and distribute the finished PTA and PET.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read